4-1BB transcriptomic expression patterns across malignancies: Implications for clinical trials of 4-1BB agonists

Yuji Uehara; Shumei Kato; Daisuke Nishizaki; Hirotaka Miyashita; Suzanna Lee; Mary K. Nesline; Sarabjot Pabla; Jeffrey M. Conroy; Paul DePietro; Heidi Ko; Jason K. Sicklick; Razelle Kurzrock

doi:10.1002/cac2.12592

PDF

Cancer Communications ›› 2024, Vol. 44 ›› Issue (10) : 1168-1172. DOI: 10.1002/cac2.12592

LETTER TO THE JOURNAL

4-1BB transcriptomic expression patterns across malignancies: Implications for clinical trials of 4-1BB agonists

Author information +

History +

Cite this article

EndNote

Ris (Procite)

Bibtex

Download citation ▾

Yuji Uehara, Shumei Kato, Daisuke Nishizaki, Hirotaka Miyashita, Suzanna Lee, Mary K. Nesline, Sarabjot Pabla, Jeffrey M. Conroy, Paul DePietro, Heidi Ko, Jason K. Sicklick, Razelle Kurzrock. 4-1BB transcriptomic expression patterns across malignancies: Implications for clinical trials of 4-1BB agonists. Cancer Communications, 2024, 44(10): 1168‒1172 https://doi.org/10.1002/cac2.12592

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Etxeberria I, Glez-Vaz J. Teijeira Á, Melero I. New emerging targets in cancer immunotherapy: CD137/4-1BB co-stimulatory axis. ESMO Open. 2020; 4(Suppl 3):e000733. CrossRef Google scholar

[2]	Wang YT, Ji WD, Jiao HM, Lu A, Chen KF, Liu QB. Targeting 4-1BB for tumor immunotherapy from bench to bedside. Front Immunol. 2022; 13: 975926. CrossRef Google scholar

[3]	Adashek JJ, Kato S, Nishizaki D, Miyashita H, De P, Lee S, et al. LAG-3 transcriptomic expression patterns across malignancies: Implications for precision immunotherapeutics. Cancer Med. 2023; 12(12): 13155-66. CrossRef Google scholar

[4]	Adashek JJ, Subbiah V, Westphalen CB, Naing A, Kato S, Kurzrock R. Cancer: slaying the nine-headed Hydra. Ann Oncol Off J Eur Soc Med Oncol. 2023; 34(1): 61-9. CrossRef Google scholar

[5]	Fujiwara Y, Kato S, Nesline MK, Conroy JM, DePietro P, Pabla S, et al. Indoleamine 2, 3-dioxygenase (IDO) inhibitors and cancer immunotherapy. Cancer Treat Rev. 2022; 110: 102461. CrossRef Google scholar

[6]	Miyashita H, Kurzrock R, Bevins NJ, Thangathurai K, Lee S, Pabla S, et al. T-cell priming transcriptomic markers: implications of immunome heterogeneity for precision immunotherapy. Npj Genomic Med. 2023; 8(1): 1-10. CrossRef Google scholar

[7]	Uehara Y, Ikeda S, Kim KH, Lim HJ, Adashek JJ, Persha HE, et al. Targeting the FGF/FGFR axis and its co-alteration allies. ESMO Open. 2022; 7(6): 100647. CrossRef Google scholar